Alkermes (ALKS) Revenue (2010 - 2026)
Alkermes' (ALKS) quarterly Revenue came in at $392.9 million in Q1 2026, up 28.19% year-on-year from $306.5 million in Q1 2025, and up 2.18% on a QoQ basis from $384.5 million in Q4 2025.
Alkermes (ALKS) Revenue (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has 17 years of Revenue data on file, last reported at $392.9 million in Q1 2026.
- On a quarterly basis, Revenue rose 28.19% year-over-year to $392.9 million in Q1 2026; TTM through Mar 2026 was $1.6 billion, a 3.21% increase from a year earlier, with the FY2025 full-year figure at $1.5 billion, down 5.25% from the prior year.
- Revenue for Q1 2026 stood at $392.9 million, up from $384.5 million in the prior quarter.
- Over the last five years, Revenue for ALKS reached as high as $617.4 million in Q2 2023 and fell as low as $3.2 million in Q2 2022.
- Historically, Revenue has averaged $334.1 million across 5 years, with a median of $378.1 million in 2024.
- Across the five-year window, Revenue slumped 98.95% in 2022 and surged 19193.66% in 2023, its largest moves.
- Year by year, Revenue stood at $304.7 million in 2022, then advanced by 23.89% to $377.5 million in 2023, then rose by 13.91% to $430.0 million in 2024, then decreased by 10.57% to $384.5 million in 2025, then grew by 2.18% to $392.9 million in 2026.
- Per Business Quant data, the three most recent Revenue figures were $392.9 million in Q1 2026, $384.5 million in Q4 2025, and $394.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 3.98 Bn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 2.26 Bn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 6.98 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 781.50 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 3.51 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 814.50 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 1.37 Bn |
| 10 | Alkermes | 8.78 Bn | 8.27 Bn | 331.33 Mn | 392.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 392.91 Mn |
| Dec 31, 2025 | 384.55 Mn |
| Sep 30, 2025 | 394.19 Mn |
| Jun 30, 2025 | 390.66 Mn |
| Mar 31, 2025 | 306.51 Mn |
| Dec 31, 2024 | 429.99 Mn |
| Sep 30, 2024 | 378.14 Mn |
| Jun 30, 2024 | 399.13 Mn |
| Mar 31, 2024 | 350.37 Mn |
| Dec 31, 2023 | 377.48 Mn |
| Sep 30, 2023 | 380.94 Mn |
| Jun 30, 2023 | 617.40 Mn |
| Mar 31, 2023 | 287.60 Mn |
| Dec 31, 2022 | 304.67 Mn |
| Sep 30, 2022 | 3.20 Mn |
| Jun 30, 2022 | 3.20 Mn |
| Mar 31, 2022 | 278.55 Mn |
| Dec 31, 2021 | 324.46 Mn |
| Sep 30, 2021 | 294.14 Mn |
| Jun 30, 2021 | 303.72 Mn |